These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31419928)

  • 41. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
    Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
    Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
    Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells.
    Han H; Jin Q; Wang Y; Chen Y; Ji J
    Chem Commun (Camb); 2015 Dec; 51(98):17435-8. PubMed ID: 26468509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereocomplex Prodrugs of Oligo(lactic acid)
    Tam YT; Huang C; Poellmann M; Kwon GS
    ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
    Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
    J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
    Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
    Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.
    Kahramanoğullari O; Fantaccini G; Lecca P; Morpurgo D; Priami C
    PLoS One; 2012; 7(12):e50176. PubMed ID: 23239976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
    Muggia F; Diaz I; Peters GJ
    Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer.
    Sehouli J
    Int J Gynecol Cancer; 2005; 15 Suppl 1():23-30. PubMed ID: 15839955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Self-Delivery Nanoparticles of Amphiphilic Methotrexate-Gemcitabine Prodrug for Synergistic Combination Chemotherapy via Effect of Deoxyribonucleotide Pools.
    Wang Y; Huang P; Hu M; Huang W; Zhu X; Yan D
    Bioconjug Chem; 2016 Nov; 27(11):2722-2733. PubMed ID: 27723981
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment.
    Marasini B; Sahu RP
    Mini Rev Med Chem; 2017; 17(11):920-927. PubMed ID: 28302042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
    Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
    ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
    Tsume Y; Incecayir T; Song X; Hilfinger JM; Amidon GL
    Eur J Pharm Biopharm; 2014 Apr; 86(3):514-23. PubMed ID: 24361461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
    Bergman AM; Adema AD; Balzarini J; Bruheim S; Fichtner I; Noordhuis P; Fodstad O; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
    Invest New Drugs; 2011 Jun; 29(3):456-66. PubMed ID: 20066470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interaction of lipophilic gemcitabine prodrugs with biomembrane models studied by Langmuir-Blodgett technique.
    Castelli F; Sarpietro MG; Rocco F; Ceruti M; Cattel L
    J Colloid Interface Sci; 2007 Sep; 313(1):363-8. PubMed ID: 17485098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
    Maréchal R; Van Laethem JL
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipid prodrug nanocarriers in cancer therapy.
    Mura S; Bui DT; Couvreur P; Nicolas J
    J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
    Ueno H; Kiyosawa K; Kaniwa N
    Br J Cancer; 2007 Jul; 97(2):145-51. PubMed ID: 17595663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.